Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Quanscient | $5,667,883 | (Nov 5, 2024)
Portal
United States
- Watertown, Massachusetts
- 20/03/2024
- Pre-Seed
- $5,000,000
Portal is a cell engineering platform company focused on enabling next generation cell engineering and cell analytics across research and clinical applications. We are implementing a simplified approach to intracellular delivery, focused on accelerating advances enabled by the new generation of RNA, gene editing, and AI-driven technologies. Portal’s initial product suite is based on a proprietary mechanical delivery system capable of delivering many different types of cargo to a broad range of cell types. The technology's ability to be used stand-alone or as an integrated component of third-party systems provides a significant opportunity to broadly impact the fields of biological research and cellular therapeutics
- Industry Biotechnology Research
- Website https://portal.bio/
- LinkedIn https://www.linkedin.com/company/portal-bio/
Related People
Armon Sharei, PhDFounder
United States -
Arlington, Massachusetts
Armon Sharei, PhD, is the Chief Executive Officer and Founder of SQZ Biotech, a biotechnology company creating innovative treatments by transforming cells into sophisticated therapeutics. Utilizing the proprietary Cell Squeeze® technology to develop a new generation of cell therapies, SQZ is creating powerful, multifunctional cell therapies for a range of diseases, with an initial focus on cancer, infectious disease and autoimmune disease.
Dr. Sharei developed the Cell Squeeze® platform during his PhD work in chemical engineering at MIT.
After his PhD, Dr. Sharei was a Ragon Institute postdoctoral Fellow at Harvard Medical School. He is co-author of 18 peer-reviewed publications and inventor on over 20 patents. In 2013, he founded SQZ Biotech. As a leader, Dr. Sharei’s motivating factor for his company is to simply make the world a better place. Dr. Sharei is driven by the potential global patient impact of the novel cell therapies SQZ can create using its breakthrough technology.
Miros | $6,535,520 | (Nov 5, 2024)
Cintoo | $40,246,701 | (Nov 5, 2024)
Further | $4,100,000 | (Nov 5, 2024)
Plato | $6,500,000 | (Nov 5, 2024)
cloudsquid | $1,000,000 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
Birl | $647,878 | (Nov 5, 2024)
Inquis Medical, Inc. | $40,000,000 | (Nov 5, 2024)
CrossBridge Bio | $10,000,000 | (Nov 5, 2024)